Eocene (EOCN) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eocene is the larger company by market cap ($3.9 million vs $3.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOCN | MBIO |
|---|---|---|
| Share price | $3.62 | $0.417 |
| Market cap | $3.87M | $3.16M |
| 1-day change | +4.69% | -7.37% |
| EPS (TTM) | $-15.21 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.80 | $1.81 |
| 52-week low | $3.12 | $0.41 |
| Distance from 52-week high | -71.72% | -76.96% |
| Analyst consensus | none | — |
| Average volume | 59.85K | 29.38K |
| Shares outstanding | 1.07M | 6.73M |
| Employees | 3 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eocene
EOCN stock →Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications.
Healthcare · Biotechnology · 3 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Healthcare · Biotechnology · 4 employees
EOCN vs MBIO FAQ
Which is bigger, Eocene or Mustang Bio?
Eocene (EOCN) is larger, with a market capitalization of $3.87M compared with $3.16M for Mustang Bio (MBIO).
Are Eocene and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.